Clinical Trials | October 13, 2025
Roche to present latest cancer care data at ESMO 2025
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Importantly, the combination of giredestrant and everolimus was well tolerated
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
_256_384.jpg)
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Subscribe To Our Newsletter & Stay Updated
